|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dipropylene glycol methyl ether | CAS 34590-94-8 | ||
| CH3OC3H6OC3H6OH | RTECS JM1575000 | ||
|
Synonyms & Trade Names Dipropylene glycol monomethyl ether, Dowanol® 50B |
DOT ID & Guide |
||
|
Exposure Limits |
NIOSH REL: TWA 100 ppm (600 mg/m3) ST 150 ppm (900 mg/m3) [skin] | ||
| OSHA PEL�: TWA 100 ppm (600 mg/m3) [skin] | |||
| IDLH 600 ppm | Conversion 1 ppm = 6.06 mg/m3 | ||
|
Physical Description Colorless liquid with a mild, ether-like odor. |
|||
|
MW: 148.2 |
BP: 408°F |
FRZ: -112°F |
Sol: Miscible |
|
VP: 0.5 mmHg |
IP: ? |
|
Sp.Gr: 0.95 |
|
Fl.P: 180°F |
UEL: 3.0% |
LEL(392°F): 1.1% |
|
| Class IIIA Combustible Liquid: Fl.P. at or above 140�F and below 200�F. | |||
|
Incompatibilities & Reactivities Strong oxidizers |
|||
|
Measurement Methods NIOSH S69 (II-2) |
|
Personal Protection & Sanitation Skin: No recommendation Eyes: No recommendation Wash skin: No recommendation Remove: No recommendation Change: No recommendation |
First Aid (See procedures) Eye: Irrigate immediately Skin: Water wash promptly Breathing: Respiratory support Swallow: Medical attention immediately |
|
Respirator Recommendations
NIOSH/OSHA Up to 600 ppm: (APF = 10) Any supplied-air respirator/(APF = 50) Any self-contained breathing apparatus with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister having a high-efficiency particulate filter/Any appropriate escape-type, self-contained breathing apparatus |
|
| Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
| Symptoms Irritation eyes, nose, throat; lassitude (weakness, exhaustion), dizziness, headache | |
|
Target Organs
Eyes, respiratory system, central nervous system |
|
| See also: INTRODUCTION |